Figure 4 Antinuclear antibodies and disease activity in SLE

Slides:

Advertisements

Similar presentations

© The Author(s) Published by Science and Education Publishing.

Advertisements

Copyright © 2004 American Medical Association. All rights reserved.

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Effects of MMF treatment in patients with SLE

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 2 Representative MSI data obtained from human joints

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Methods to detect trough levels of therapeutic antibodies

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 1 Location of HLA variants known to be associated

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 4 Post-test probability as a function of pre-test

Figure 2 Algorithm for immunosuppressive treatment

Figure 1 IFA testing for identifying the presence of ANAs

Figure 2 Cas9 targeting using crRNA (CRISPR

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Principles of therapeutic ultrasound

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes.

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Figure 1 The current model of the pathogenesis of SLE

Jack C. O’Brien, Benjamin F. Chong

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 The release of DNA from dead and dying cells

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Cellular contributions to the development of SLE

Jack C. O’Brien, Benjamin F. Chong

Association of B cell TLR4 levels to disease activity.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.

Figure 2 Cell-based assay demonstrating differential binding of AChR antibodies to the adult and fetal receptorsThe fetal (gamma subunit specific) and.

Association of MRI findings and serum autoantibodies in diffuse neuropsychiatric systemic lupus erythematosus. Association of MRI findings and serum autoantibodies.

Nat. Rev. Rheumatol. doi: /nrrheum

Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Two-tier.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Presentation transcript:

Figure 4 Antinuclear antibodies and disease activity in SLE Figure 4 | Antinuclear antibodies and disease activity in SLE. Levels of anti-DNA and anti-Sm antibodies were determined in the serum of a patient with systemic lupus erythematosus (SLE). Flares of disease activity resulted initially in treatment with cyclophosphamide and methylprednisolone, and subsequently with prednisone. In these studies, assay of anti-Sm antibodies (which bind to small nuclear riboproteins) was performed by passive haemagglutination (PHA), whereas anti-DNA antibody levels were determined by a filter-binding assay in which the presence of antibodies is detected by the capture of a radiolabelled DNA substrate with a nitrocellulose filter. In the absence of antibody binding, the DNA does not bind to the filter. Permission obtained from The Journal of Rheumatology © McCarty, G. A. et al. Independent expression of autoantibodies in systemic lupus erythematosus. J. Rheumatol. 9, 691–695 (1982). Permission obtained from The Journal of Rheumatology © McCarty, G. A. et al. Independent expression of autoantibodies in systemic lupus erythematosus. J. Rheumatol. 9, 691–695 (1982) Pisetsky, D. S. (2015) Anti-DNA antibodies — quintessential biomarkers of SLE Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.151